Malignant gliomas are the most frequent type of primary brain tumors. Patients' outcome has not improved despite new therapeutics, thus underscoring the need for a better understanding of their genetics and a fresh approach to treatment. The lack of reproducibility in the classification of many gliomas presents an opportunity where genomics may be paramount for accurate diagnosis and therefore best for therapeutic decisions. The aim of this work is to identify large and focal copy number abnormalities (CNA) and loss of heterozygosity (LOH) events in a malignant glioma population. We hypothesized that these explorations will allow discovery of genetic markers that may improve diagnosis and predict outcome. DNA from glioma specimens were subjected to CNA and LOH analyses. Our studies revealed more than 4000 CNA and several LOH loci. Losses of chromosomes 1p and/or 19q, 10, 13, 14, and 22 and gains of 7, 19, and 20 were found. Several of these alterations correlated significantly with histology and grade. Further, LOH was detected at numerous chromosomes. Interestingly, several of these loci harbor genes with potential or reported tumor suppressor properties. These novel genetic signatures may lead to critical insights into diagnosis, classification, prognosis, and design of individualized therapies.
Get full access to this article
View all access options for this article.
References
1.
AcharyaC.R., HsuD.S., AndersC.K., AnguianoA., SalterK.H., WaltersK.S.et al.2008. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA, 299:1574–1587.
2.
AldapeK., BurgerP.C., PerryA.2007. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med, 131:242–251.
3.
BaumanG.S., InoY., UekiK., ZlatescuM.C., FisherB.J., MacdonaldD.R.et al.2000. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys, 48:825–830.
4.
BelloM.J., LeoneP.E., VaqueroJ., De CamposJ.M., KusakM.E., SarasaJ.L.et al.1995. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer, 64:207–210.
5.
BeroukhimR., LinM., ParkY., HaoK., ZhaoX., GarrawayL.A.et al.2006. Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arrays. PLoS Comput Biol, 2:e41.
6.
CairncrossJ.G., UekiK., ZlatescuM.C., LisleD.K., FinkelsteinD.M., HammondR.R.et al.1998. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst, 90:1473–1479.
7.
Cancer Genome Atlas Research Network. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455:1061–1068.
8.
ColmanH., ZhangL., SulmanE.P., McDonaldJ.M., ShooshtariN.L., RiveraA.et al.2010. A multigene predictor of outcome in glioblastoma. Neuro Oncol, 12:49–57.
9.
CowellJ.K., LoK.C., LuceJ., HawthornL.2010. Interpreting aCGH-defined karyotypic changes in gliomas using copy number status, loss of heterozygosity and allelic ratios. Exp Mol Pathol, 88:82–89.
10.
DeorahS., LynchC.F., SibenallerZ.A., RykenT.C.2006. Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus, 20:E1.
FreijeW.A., Castro-VargasF.E., FangZ., HorvathS., CloughesyT., LiauL.M.et al.2004. Gene expression profiling of gliomas strongly predicts survival. Cancer Res, 64:6503–6510.
13.
FritzB., SchubertF., WrobelG., SchwaenenC., WessendorfS., NesslingM.et al.2002. Microarray-based copy number and expression profiling in dedifferentiated and pleomorphic liposarcoma. Cancer Res, 62:2993–2998.
14.
GianniniC., BurgerP.C., BerkeyB.A., CairncrossJ.G., JenkinsR.B., MehtaM.et al.2008. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol, 18:360–369.
15.
GravendeelL.A.M., KouwenhovenM.C., GevaertO., de RooiJ.J., StubbsA.P., DuijmJ.E.et al.2009. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res, 69:9065–9072.
16.
GuptaM., DjalilvandA., BratD.J.2005. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Anat Pathol, 124:755–768.
17.
HegiM.E., DiserensA.C., GorliaT., HamouM.F., de TriboletN., WellerM.et al.2005. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 352:997–1003.
18.
HuangT.T., SarkariaS.M., CloughesyT.F., MischelP.S.2009. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics, 6:500–512.
19.
JeukenJ.W., SprengerS.H., WesselingP., MacvilleM.V., Von DeimlingA., TeepenH.L.et al.1999. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol, 58:606–12.
20.
KantarjianH., SawyersC., HochhausA., GuilhotF., SchifferC., Gambacorti-PasseriniC.et al.2002. International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med, 346:645–652.
21.
KimL., HochbergF.H., ThorntonA.F., HarshG.R.4th, PatelH., FinkelsteinD.et al.1996. Procarbazine, lomustine and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas. J Neurosurg, 85:602–607.
22.
KleihuesP., LubbeJ., WatanabeK., von AmmonK., OhgakiH.1994. Genetic alterations associated with glioma progression. Verh Dtsch Ges Pathol, 78:43–47.
23.
KrausJ.A., KoopmannJ., KaskelP., MaintzD., BrandnerS., SchrammJ.et al.1995. Shared allelic losses on chrom. 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol, 54:91–95.
24.
LeeY., ScheckA.C., CloughesyT.F., LaiA., DongJ., FarooqiH.K.et al.2008. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics, 1:52.
25.
LiA., WallingJ., AhnS., KotliarovY., SuQ., QuezadoM.et al.2009. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res, 69:2091–2099.
26.
LoK.C., RossiM.R., LaDucaJ., HicksD.G., TurpazY., HawthornL.et al.2007. Candidate glioblastoma development gene identification using concordance between copy number abnormalities and gene expression level changes. Genes Chromosomes Cancer, 46:875–894.
27.
McDonaldJ.M., SeeS.J., TremontI.W., ColmanH., GilbertM.R., GrovesM.et al.2005. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer, 104:1468–1477.
28.
NakamuraM., KishiM., SakakiT., HashimotoH., NakaseH., ShimadaK.et al.2003. Novel tumor suppressor loci on 6q22–23 in primary central nervous system lymphomas. Cancer Res, 63:737–741.
29.
NigroJ.M., TakahashiM.A., GinzingerD.G., LawM., PasseS., JenkinsR.B.wt al.2001. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol, 158:1253–1262.
30.
NovellinoL., De FilippoA., DehoP., PerroneF., PilottiS., ParmianiG.et al.2008. PTPRK negatively regulates transcriptional activity of wild type and mutated oncogenic β-catenin and affects membrane distribution of β-catenin/E-cadherin complexes. Cell Signal, 20:872–883.
PaoW., MillerV., ZakowskiM., DohertyJ., PolitiK., SarkariaI.et al.2004. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 101:13306–13311.
33.
ParsonsD.W., JonesS., ZhangX., LinJ.C., LearyR.J., AngenendtP.et al.2008. An integrated genomic analysis of human glioblastoma multiforme. Science, 321:1807–1812.
34.
PegramM.D., LiptonA., HayesD.F., WeberB.L., BaselgaJ.M., TripathyD.et al.1998. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol, 16:2659–2671.
35.
PelloskiC.E., LinE., ZhangL., YungW.K., ColmanH., LiuJ.L.et al.2006. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res, 12:3935–3941.
36.
Pérez-SolerR., ChachouaA., HammondL.A., RowinskyE.K., HubermanM., KarpD.et al.2004. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol, 22:3238–3247.
37.
PerryA. 2001. Oligodendroglial neoplasms: current concepts, misconceptions, and folklore. Adv Anat Pathol, 8:183–199.
38.
PhillipsH.S., KharbandaS., ChenR., ForrestW.F., SorianoR.H., WuT.D.et al.2006. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell, 9:157–173.
39.
ReifenbergerJ., ReifenbergerG., LiuL., JamesC.D., WechslerW., CollinsV.P.1994. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol, 145:1175–1190.
40.
RichJ.N., HansC., JonesB, IversenE.S., McLendonR.E., RasheedB.K.et al.2005. Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res, 65:4051–4058.
41.
SarkariaJ.N., YangL., GroganP.T., KitangeG.J., CarlsonB.L., SchroederM.A.et al.2007. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther, 6:1167–1174.
SmithJ.S., PerryA., BorellT.J., LeeH.K., O'FallonJ., HosekS.M.et al.2000. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol, 18:636–645.
44.
StarrT.K., AllaeiR., SilversteinK.A., StaggsR.A., SarverA.L., BergemannT.L.et al.2009. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science, 323:1747–1750.
Von DeimlingA., NagelJ., BenderB., LenartzD., SchrammJ., LouisD.N.et al.1994. Deletion mapping of chromosome 19 in human gliomas. Int J Cancer, 57:676–680.
ZhuH., AcquavivaJ., RamachandranP., BoskovitzA., WoolfendenS., PfannlR.et al.2009. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci USA, 106:2712–2716.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
